



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 034. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

NATCO Pharma announces USFDA tentative approval of Oseltamivir Phosphate Capsules

Hyderabad, India, March 18, 2014

Natco Pharma Limited (NSE: NATCOPHARM) announced today that it has received **tentative approval** of Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base) and 75 mg (base) by the United States Food & Drug Administration (USFDA). Natco is partnered with Alvogen for marketing.

Natco may have First to File approval status for the Abbreviated New Drug Application (ANDA), contingent upon successful litigation outcome of original drug patent 5,763,483 (the '483 patent). TAMIFLU® (Roche's trade name for Oseltamivir Phosphate) had U.S. sales of approximately \$495 Million for twelve months ending September 2013, according to IMS Health.

Forwarded for favour of Publication

For NATCO PHARMA LIMITED

A handwritten signature in black ink, appearing to read "M. Adinarayana".

M.ADINARAYANA
COMPANY SECRETARY &
VICE PRESIDENT (LEGAL & CORP. AFFAIRS)